title: Antiangiogenic therapy and p53.
authors.affiliation: Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Browder
authors.forename: Judah
authors.initials: J
authors.lastname: Folkman
authors.forename: Philip
authors.initials: P
authors.lastname: Hahnfeldt
authors.forename: John
authors.initials: J
authors.lastname: Heymach
authors.forename: Lynn
authors.initials: L
authors.lastname: Hlatky
authors.forename: Mark
authors.initials: M
authors.lastname: Kieran
authors.forename: Michael S
authors.initials: MS
authors.lastname: Rogers
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D016158:Genes, p53; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009389:Neovascularization, Pathologic; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000276:immunology / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor; D014407:Tumor Cells, Cultured
chemical_list: D020533:Angiogenesis Inhibitors; D006133:Growth Substances; D017978:Receptors, Growth Factor; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor